Which semaglutide products are FDA-approved, and for what?
The FDA has approved three branded semaglutide products, each with a distinct indication and route of administration:
| Brand | Route | Frequency | FDA-approved indication |
|---|---|---|---|
| Ozempic | Injectable | Weekly | Type 2 diabetes; cardiovascular risk reduction |
| Wegovy | Injectable | Weekly | Chronic weight management (BMI ≥30, or ≥27 with weight-related condition) |
| Rybelsus | Oral tablet | Daily | Type 2 diabetes; not indicated for weight management |
| Compounded semaglutide | Injectable (patient-specific) | Weekly | Not FDA-approved; prescribed per patient and filled by a 503A pharmacy |
These branded products went through the FDA’s New Drug Application process. They have defined manufacturing standards, clinical trial evidence, labeled indications, and approved dosing schedules. FDA approval means the agency reviewed safety and efficacy data and found the drug appropriate for its labeled use.
What is compounded semaglutide, and how does it differ?
Compounded semaglutide is a preparation made by a licensed compounding pharmacy using semaglutide as the active ingredient. It is not an FDA-approved drug. That statement is sometimes misread as a red flag, but it reflects how the compounding regulatory framework works rather than a product deficiency.
Under federal law, licensed 503A compounding pharmacies can prepare patient-specific formulations using bulk drug substances when a licensed practitioner writes a prescription. Compounded preparations are regulated differently from manufactured drugs: they do not go through the New Drug Application, and they are not evaluated by FDA for safety and efficacy in the same process that branded drugs are.
The practical distinction for patients: compounded semaglutide contains the same active molecule as Ozempic and Wegovy. The compounding process, sourcing, and quality controls are governed by the pharmacy’s state board, USP standards, and the oversight of the prescribing clinician — not by an FDA product-level approval.
If it is not FDA-approved, how is compounded semaglutide dispensed?
Compounded semaglutide is dispensed under Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs medication a licensed pharmacy prepares for a named patient once a clinician has prescribed it. That process is not a substitute for FDA approval, and the preparation does not carry one. Ozempic, Wegovy and Rybelsus went through the approval process; the compounded preparation did not.
Much of what is written about this online is still framed around the years when the branded semaglutide injections sat on the FDA drug shortage list and access expanded quickly. FDA has since determined those injection shortages resolved. What governs your own prescription is who wrote it, what is in the vial, and which pharmacy filled it.
PepScribe’s clinical partners work only with licensed 503A compounding pharmacies in the United States. Compounded semaglutide dispensed through our platform is prepared domestically under physician prescription — no hidden overseas supply chain.
Compounded semaglutide is the same active molecule as Ozempic and Wegovy — but a legally distinct preparation that is not FDA-approved.
Why does the branded vs. compounded distinction matter for your decision?
Understanding the difference between branded and compounded semaglutide helps you ask the right questions when speaking with a clinician:
- Insurance coverage: Branded semaglutide may be covered by insurance with a qualifying diagnosis. Compounded semaglutide is almost never covered. Cost structure is a real variable in determining which route makes sense for you.
- Formulary and dosing flexibility: Branded products come in fixed dose-step titration schedules. Compounded formulations can be prepared at doses outside that ladder when clinically appropriate, which some clinicians use for patients who need to hold a dose or taper more gradually.
- Sourcing transparency: With compounded semaglutide, it matters significantly where the pharmacy sources its bulk active pharmaceutical ingredient. Reputable 503A pharmacies use USP-grade, domestically sourced semaglutide. Gray-market or overseas sources carry real purity and contamination risks.
- Ongoing regulatory landscape: Rules around compounded GLP-1 preparations keep moving. A clinician working in this space should be able to tell you where things stand and how it affects your prescription.
What does the clinical evidence show for semaglutide and weight management?
The branded semaglutide approval for weight management (Wegovy) was supported by the STEP clinical trial program, a set of randomized, placebo-controlled trials. The STEP 1 trial, published in the New England Journal of Medicine, enrolled adults with overweight or obesity and found that weekly semaglutide 2.4 mg led to a mean weight reduction of approximately 15% over 68 weeks, compared to approximately 2.4% in the placebo group.
These are the trials that FDA reviewed for the Wegovy approval. They establish a clinical evidence base for the semaglutide molecule. The evidence for the branded product informs clinical judgment about compounded formulations using the same active ingredient, though compounded semaglutide itself has not been separately evaluated in its own large-scale randomized trials.
Clinicians prescribing compounded semaglutide draw on the published evidence for semaglutide as a molecule while applying their judgment about the individual patient, their medical history, and the current legal landscape.
How do telehealth platforms fit into this picture?
Telehealth platforms like PepScribe operate as the patient-facing intake and consultation layer. A licensed clinician conducts a medical evaluation, reviews your goals, health history, and any contraindications, and if appropriate, prescribes compounded semaglutide to a licensed 503A pharmacy that ships directly to you.
What this means for patient safety: the key variables are the quality of the clinical evaluation, the pharmacy’s 503A credentials, and the sourcing of the active pharmaceutical ingredient. A well-run telehealth program is explicit about all three. One that downplays the distinction between branded and compounded semaglutide, or that avoids discussing sourcing, warrants scrutiny.
PepScribe’s compounded semaglutide is prepared exclusively in the USA by licensed 503A pharmacies. Every prescription is written by a licensed clinician after a medical review. The platform does not manufacture drugs, does not source internationally, and does not dispense without a clinician relationship.
Frequently asked questions about semaglutide FDA approval
Is semaglutide FDA-approved?
Yes — branded semaglutide products (Ozempic, Wegovy, Rybelsus) are FDA-approved. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management in adults with obesity or overweight with a weight-related condition. Compounded semaglutide is not an FDA-approved drug; it is a separate category prepared by licensed 503A compounding pharmacies under physician oversight.
Can I get compounded semaglutide from a telehealth provider?
Compounded semaglutide can be prescribed by a licensed clinician and dispensed by a licensed 503A compounding pharmacy in the USA, which prepares it for the named patient once the prescription is written. It is not an FDA-approved drug. A telehealth clinician evaluates your medical history and goals, then determines whether compounded semaglutide is appropriate for you.
Is compounded semaglutide the same as Ozempic or Wegovy?
Compounded semaglutide contains the same active molecule (semaglutide) but is not the same drug as Ozempic or Wegovy. Branded drugs go through FDA approval with manufacturing and label standards that compounded preparations do not. They are legally and regulatorily distinct products.
What does 503A mean for compounded semaglutide?
Section 503A of the Federal Food, Drug, and Cosmetic Act governs medication a licensed pharmacy prepares for a named patient once a clinician has prescribed it. Preparations made under it are exempt from the FDA premarket approval process. That is the line between the two categories here: Ozempic, Wegovy and Rybelsus went through FDA approval, and compounded semaglutide did not.
Who is a candidate for compounded semaglutide?
Eligibility is determined by a licensed clinician based on BMI, weight-related health indicators, medical history, and medications. There is no way to self-qualify; a medical evaluation is required.
How is PepScribe compounded semaglutide sourced?
PepScribe partners exclusively with licensed 503A compounding pharmacies in the United States. No hidden overseas supply chain — every dose is compounded domestically under physician prescription.
